PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
No Data
No Data available this quarter, please select a different quarter.
3.07
Net debt 3-4x EBITDA - Concerning leverage levels. Howard Marks would demand exceptional business stability. Essential to verify Debt-to-Equity and Interest Coverage.
No Data
No Data available this quarter, please select a different quarter.
4.95
Current ratio above 2.0 - Rock-solid working capital position. Benjamin Graham would approve, but check if excess current assets hurt ROE. Consider examining Cash Conversion Cycle for efficiency.
No Data
No Data available this quarter, please select a different quarter.